

## Research Article

# Determination of Fluconazole in Bulk Drug and its Solid Formulations by Acid-base Titration in Non-aqueous Medium

Vamsi Krishna Penmatsa and Basavaiah Kanakapura

Department of Chemistry, University of Mysuru, Manasagangotri, 570006 Mysuru, Karnataka, India

### Abstract

**Background:** Fluconazole (FLK) is a synthetic triazole derivative antifungal agent that has been shown to be effective against a wide range of systemic and superficial fungal infections. **Objective:** Two simple, rapid, reliable, precise and accurate and cost-effective non-aqueous titrimetric procedures have been developed for the determination of FLK in bulk drug and its pharmaceutical formulations. **Materials and Methods:** The methods are based on the titration of the drug with perchloric acid in glacial acetic acid with the visual end point detection using crystal violet as indicator or the potentiometric end point using a combined double junction pH electrode system. **Results:** The methods were applicable over the range of 2.0-15.0 mg FLK and the calculations are based on a 1:2 reaction stoichiometry. The procedures were also applied for the determination of FLK in its dosage forms and the results were found to be in a good agreement with those obtained by the reference method. The precision results expressed by intra-day and inter-day relative standard deviation values were good (RSD<0.75%). The accuracy was satisfactory as well (RE $\leq$ 1.30%). Excipients used as additives in pharmaceutical formulations did not interfere in the proposed procedures as shown by the recovery study via standard addition technique recoveries in the range 99.23-101.03% with a standard deviation of  $\leq$ 0.91%. **Conclusion:** The proposed methods were applied for determination of the FLK in tablets. Both the methods were validated and can be suggested for routine analysis in quality control department.

**Key words:** Fluconazole, non-aqueous titrimetry, pharmaceuticals, crystal violet, potentiometry

**Citation:** Vamsi Krishna Penmatsa and Basavaiah Kanakapura, 2018. Determination of fluconazole in bulk drug and its solid formulations by acid-base titration in non-aqueous medium. *Insight Pharmaceutical Sciences*, 8: 13-20.

**Corresponding Author:** Basavaiah Kanakapura, Department of Chemistry, University of Mysuru, Manasagangotri, 570006 Mysuru, Karnataka, India

**Copyright:** © 2018 Vamsi Krishna Penmatsa and Basavaiah Kanakapura. This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Competing Interest:** The authors have declared that no competing interest exists.

**Data Availability:** All relevant data are within the paper and its supporting information files.

## INTRODUCTION

Fluconazole (FLK) chemically known as (2-(2,4-difluorophenyl)-1,3-bis (1h-1,2,4,-triazol-1-yl) propan-2-ol)<sup>1</sup>. Figure 1 is a synthetic triazole derivative antifungal agent that has been shown to be effective against a wide range of systemic and superficial fungal infections<sup>2</sup>. The FLK is almost completely absorbed (>90%) from the gastrointestinal tract after oral administration and about 11-12% of the drug in plasma is protein bound. The recommended dosage of FLK is generally 100-200 mg once daily and the time to attain peak concentration in plasma is 1.7-4.3 h after single dose drug administration. The FLK has a long half-life ( $32 \pm 5$  h) and is excreted predominantly unchanged in urine<sup>3,4</sup> ( $75 \pm 9\%$ ).

A number of different analytical investigations have been done to determine the drug content in pharmaceuticals and body fluids; also for dissolution, bioequivalence and pharmacokinetic studies. Recently, Correa and Salgado<sup>5</sup> have reviewed the FLK properties and methods for its determination with emphasis on body fluids by HPLC. The drug in body biological fluids has been determined by liquid chromatography-tandem mass spectrometry (LCMS)<sup>6-10</sup>, gas chromatography (GC)<sup>11-17</sup>, GC-MS<sup>18</sup>, micellar electrokinetic capillary chromatography<sup>19</sup>, ISE-potentiometry<sup>20</sup> and microbiological assay<sup>21-24</sup>.

According to the literature survey, the drug in bulk and dosage forms has been quantitated by UV-spectrophotometry<sup>25-35</sup>, visible spectrophotometry<sup>36-38</sup>, fluorospectrometry<sup>39-41</sup>, proton NMR spectroscopy<sup>42</sup>, ISE-potentiometry<sup>20</sup>, thin layer chromatography<sup>43</sup>, high performance thin layer chromatography<sup>44,45</sup>, ultra performance liquid chromatography<sup>46,47</sup>, microbiological assays<sup>25,48-50</sup> and high performance liquid chromatography<sup>25,28,34,47,48,50-58</sup>. Three non-aqueous titrimetric methods in United states pharmacopeia<sup>59</sup>, European pharmacopoeia<sup>60</sup> and British pharmacopoeia<sup>61</sup> are also reported for estimation of FLK in bulk drug in with perchloric acid used as titrant and the end point being located potentiometrically.

In spite of its inherent simplicity, speed, cost effectiveness, excellent accuracy and precision, no visual titrimetric method has ever been reported for FLK. Three non-aqueous titrimetric procedures recommended by the pharmacopoeias<sup>59-61</sup> require large quantities of drug (about 200 mg for each titration) and 0.1 M HClO<sub>4</sub> with potentiometric end point detection which are slow and expensive in terms of strength of HClO<sub>4</sub>.

The present study describes two simple and accurate titrimetric procedures for the determination of FLK in pure as well as in tablet formulations. The methods involve the titration of FLK with 0.01 M perchloric acid in acetic acid




Fig. 1: Structure of fluconazole

medium and end point being detected either visually using crystal violet as indicator or potentiometrically using combined double junction pH electrode. The methods cut down the cost per analysis since they employ 0.01 M HClO<sub>4</sub> and a few milligram of FLK per analysis. Visual titration can be completed in less than 5 min there by realizing high throughput.

## MATERIALS AND METHODS

**Apparatus:** A Metrohm Swiss made 809 titrando auto titrator with combined double junction pH electrode system for non-aqueous acid-base titration was used for potentiometric titration. The KCl salt bridge was replaced with saturated solution of LiCl in ethanol.

**Reagents:** All chemicals were used for analytical reagent grade. All solutions are made in glacial acetic acid (S.D. Fine chem., Mumbai, India) unless mentioned otherwise.

**Perchloric acid (0.01 M):** The stock solution of (0.1 M) perchloric acid (S.D. Fine chem., Mumbai, India) was diluted appropriately with glacial acetic acid to get a working solution of 0.01 M perchloric acid and standardized with pure potassium hydrogen phthalate and crystal violet as indicator<sup>62</sup>.

**Crystal violet indicator (0.1%):** Prepared by dissolving 50 mg of dye (S.D. Fine chem., Mumbai, India) in 50 mL of glacial acetic acid.

**Standard drug solution:** Stock standard solution containing 2 mg mL<sup>-1</sup> pure drug was prepared by dissolving the suitable amount of FLK (Dr. Reddy's laboratories limited, Hyderabad, India) in glacial acetic acid.

**Visual titration:** An aliquot of the standard drug solution containing 2.0-15.0 mg of FLK was measured accurately and transferred into a clean and dry 100 mL titration flask and the total volume was brought to 10 mL with glacial acetic acid. Two drops of crystal violet indicator were added and titrated with standard 0.01 M perchloric acid to a blue colour end point. An indicator blank titration was performed and corrections to the sample titration were applied. The amount of the drug in the measured aliquot was calculated from:

$$\text{Amount (mg)} = VM_wR/n$$

where, V is volume of perchloric acid consumed (mL),  $M_w$  is relative molecular mass of the drug, R is molarity of the perchloric acid and n is number of moles of perchloric acid reacting with each mole of FLK.

**Potentiometric titration:** An aliquot of the standard drug solution equivalent to 2.0-15.0 mg of FLK was measured accurately and transferred into a clean and dry 100 mL beaker and the solution was diluted to 25 mL by adding glacial acetic acid. The combined double junction pH electrode was dipped in the solution. The contents were stirred with magnetic stirrer and the titrant (0.01 M HClO<sub>4</sub>) was added from a micro burette. Near the equivalence point, titrant was added in 0.01 mL increments. After each addition of titrant, the solution was stirred magnetically for 30 sec and the steady potential was noted. The addition of titrant was continued until there was non-significant change in potential on further addition of titrant. The equivalence point was determined by applying the graphical method. The amount of the drug in the measured aliquot was calculated as described under visual titration.


**Procedure for formulations:** Two brands of tablets, Nuforce-150 (from Pharma Force Lab, Himachal Pradesh, India) and AF-150 (from Ontop Pharmaceuticals pvt. Ltd., Bangalore, India) used in the investigation were purchased from commercial sources in the local market.

Twenty tablets were weighed and ground into a fine powder. An amount of tablet power equivalent of 50 mg FLK was weighed accurately and transferred into a 25 mL calibrated flask and 10 mL of glacial acetic acid was added. The contents sonicated for 10 min, diluted to the mark with glacial acetic acid, mixed well and filtered using a Whatmann No. 42 filter paper. A suitable aliquot was next subjected to analysis by applying the general procedures as described earlier.


## RESULTS AND DISCUSSION


Titration in non-aqueous medium is the most common method adopted by pharmacopoeias for weakly acidic or basic pharmaceuticals since it serves a double purpose: A solvent for weak acids/bases and tends to enhance the weakly basic properties of weak bases and weakly acidic property of weak acids due to the non-leveling effect of the medium.

The present methods are based on the neutralization reaction involving the basic property of FLK and employ two techniques. The methods are based on the principle that substances which are weakly basic in aqueous medium, when dissolved in non-aqueous solvents exhibit enhanced basicity thus, allowing their easy determination. Acetic acid is the most commonly employed medium for titration of weak bases due to its protophilic and protogenic properties and its ability to donate protons and accept protons<sup>63</sup> as follows:




When a strong acid such as HClO<sub>4</sub> is dissolved in a weaker acid such as CH<sub>3</sub>COOH, the latter is forced to act as a base and accepts a proton from HClO<sub>4</sub> to form an onium ion<sup>64</sup>. The onium ion formed (CH<sub>3</sub>COOH<sub>2</sub><sup>+</sup>) can very readily give up its proton to react with FLK so the basic properties of the drug is enhanced and hence, titration between FLK and HClO<sub>4</sub> becomes easy. The reactions occurring are as follows:





The overall reaction is



Crystal violet gave satisfactory end point for the amounts of analyte and concentration of titrant employed. A steep raise in the potential was observed at the equivalence point with potentiometric end point detection (Fig. 2a, b). With both methods of equivalence point detection, a reaction stoichiometry of 1:2 (Drug:Titrant) was obtained which served as the basis for calculation. Using 0.01 M perchloric acid, 2.0-15.0 mg of FLK was conveniently determined. The relationship between the drug amount and the titration end point was examined. The linearity between two parameters is apparent from the correlation coefficients of 0.9997 and 0.99997 obtained by the method of least squares for visual and potentiometric methods, respectively. From this it is implied that the reaction between FLK and perchloric acid proceeds stoichiometrically in the ratio 1:2 in the range studied.

### Method validation

**Intra-day and inter-day accuracy and precision:** The precision of the methods was evaluated in terms of intermediate precision (intra-day and inter-day). Three different amounts of FLK within the range of study in each method were analysed in seven and five replicates in method A and method B, respectively, during the same day (intra-day precision) and five consecutive days (inter-day precision). For inter-day precision, each day analysis was performed in triplicate and pooled-standard deviation was calculated. The RSD values of intra-day and inter-day studies for FLK showed that the precision of the methods was good (Table 1). The accuracy of the methods was determined by the percent mean deviation from known concentration and results are presented in Table 1.




Fig. 2(a-b): Relationship between titrant and drug

**Ruggedness of the methods:** Method ruggedness was expressed as the RSD of the same procedure applied by four different analysts as well as using four different burettes. The inter-analysts RSD were less than 0.81% whereas the inter-burettes RSD for the same FLK amounts ranged from 0.16-0.80% suggesting that the developed method was rugged (Table 2).

**Application:** The described titrimetric procedures were successfully applied to the determination of FLK in its pharmaceutical formulations (Nuforce-150 and AF-150). The results obtained from Table 3 were statistically compared with the reference method<sup>28</sup>. The reference UV-spectrophotometric method involved the measurement of the absorbance of FLK tablet solution at 260 nm in HCl media. The results obtained by the proposed methods agreed well with those of reference method and with the label claim. The results were also compared statistically by a Student's t-test for accuracy and by a variance F-test for precision with those of the reference

method at 95% confidence level as summarized in Table 3. The results showed that the calculated t and F-values did not exceed the tabulated values inferring that proposed methods are as accurate and precise as the reference method.

**Recovery study:** Accuracy and the reliability of the methods were further ascertained by performing recovery experiments. To a fixed amount of drug in formulation (pre-analysed): Pure drug at three different levels was added and the total was found by the proposed methods. Each test was repeated three times. Table 4 shows that recoveries

Table 1: Intra-day and inter-day accuracy and precision

| Method                            | FLK (mg) | Intra-day accuracy and precision |        |         | Inter-day accuracy and precision |        |         |
|-----------------------------------|----------|----------------------------------|--------|---------|----------------------------------|--------|---------|
|                                   |          | FLK found                        | RE (%) | RSD (%) | FLK found                        | RE (%) | RSD (%) |
| Visual titrimetry (n = 7)         | 5        | 5.02                             | 0.40   | 0.75    | 4.99                             | -0.20  | 0.53    |
|                                   | 10       | 10.13                            | 1.30   | 0.34    | 9.98                             | -0.20  | 0.43    |
|                                   | 15       | 15.12                            | 0.80   | 0.25    | 14.88                            | -0.80  | 0.23    |
| Potentiometric titrimetry (n = 5) | 5        | 5.02                             | 0.40   | 0.44    | 4.96                             | -0.80  | 0.18    |
|                                   | 10       | 10.09                            | 0.90   | 0.05    | 9.96                             | -0.40  | 0.38    |
|                                   | 15       | 15.11                            | 0.73   | 0.09    | 14.95                            | -0.33  | 0.12    |

RE: Relative error and RSD: Relative standard deviation

Table 2: Method ruggedness expressed as intermediate precision (RSD %)

| Method                    | FLK (mg) | Ruggedness                     |                                |
|---------------------------|----------|--------------------------------|--------------------------------|
|                           |          | Inter-analysts (RSD %) (n = 4) | Inter-burettes (RSD %) (n = 4) |
| Visual titrimetry         | 5        | 0.81                           | 0.80                           |
|                           | 10       | 0.46                           | 0.40                           |
|                           | 15       | 0.31                           | 0.27                           |
| Potentiometric titrimetry | 5        | 0.35                           | 0.23                           |
|                           | 10       | 0.12                           | 0.34                           |
|                           | 15       | 0.14                           | 0.16                           |

Table 3: Results of assay in tablets and comparison with the reference method

| Tablet brand name** | Nominal amount (mg) | Found* (Percent of label claim ± SD) |                                      |                                     |
|---------------------|---------------------|--------------------------------------|--------------------------------------|-------------------------------------|
|                     |                     | Reference method                     | Proposed method                      |                                     |
|                     |                     |                                      | Visual titrimetry                    | Potentiometric titrimetry           |
| AF-150              | 150                 | 99.2 ± 0.91                          | 100.2 ± 1.04<br>t = 1.6<br>F = 1.29  | 100.1 ± 0.64<br>t = 1.88<br>F = 2.0 |
| Nuforce-150         | 150                 | 98.9 ± 0.95                          | 99.78 ± 0.44<br>t = 1.88<br>F = 4.76 | 99.9 ± 0.46<br>t = 2.11<br>F = 4.3  |

\*Average of five determinations, tabulated t-value at the 95% confidence level is 2.77 and tabulated F-value at the 95% confidence level is 6.39

Table 4: Results of recovery study by standard addition method

| Tablet      | Visual titrimetry |               |            |                                  | Potentiometric titrimetry |               |            |                                  |
|-------------|-------------------|---------------|------------|----------------------------------|---------------------------|---------------|------------|----------------------------------|
|             | FLK tablet (mg)   | Pure FLK (mg) | Total (mg) | Pure FLK recovered* Percent ± SD | FLK tablet (mg)           | Pure FLK (mg) | Total (mg) | Pure FLK recovered* Percent ± SD |
| AF-150      | 2.06              | 5.0           | 7.07       | 100.10 ± 0.65                    | 2.06                      | 5.0           | 7.02       | 99.39 ± 0.17                     |
|             | 2.06              | 7.5           | 9.55       | 99.89 ± 0.91                     | 2.06                      | 7.5           | 9.53       | 99.72 ± 0.06                     |
|             | 2.06              | 10.0          | 12.18      | 100.97 ± 0.63                    | 2.06                      | 10.0          | 12.02      | 99.70 ± 0.12                     |
| Nuforce-150 | 2.10              | 5.0           | 7.17       | 101.03 ± 0.65                    | 2.10                      | 5.0           | 7.06       | 99.44 ± 0.29                     |
|             | 2.10              | 7.5           | 9.62       | 100.24 ± 0.48                    | 2.10                      | 7.5           | 9.56       | 99.55 ± 0.16                     |
|             | 2.10              | 10.0          | 12.15      | 100.44 ± 0.38                    | 2.10                      | 10.0          | 12.01      | 99.23 ± 0.13                     |

\*Mean value of three determinations

were in the range from 99.23-101.03% indicating that commonly added excipients to tablets did not interfere in the determination.

### CONCLUSION

Many of the reported methods suffer from such drawbacks as high cost, multiple steps and also several clean-up steps (HPLC). They are time consuming and often poorly reproducible, some require toxic organic solvents. Any method chosen for routine analysis should be reasonably simple, used materials should readily available in the laboratory or readily obtainable and require a minimum amount of equipment. These objectives have been fulfilled by the two titrimetric procedures developed. The methods provide two simple procedures for the determination of FLK in pure form and its dosage form. The present methods have the distinct advantages over the previously reported methods in terms of speed, cost effectiveness, simplicity, sensitivity, accuracy and ease of performance does not need expensive and highly sophisticated equipment or high-cost organic solvents which are required for HPLC technique. Therefore, the proposed method can be used in laboratories where modern and expensive instruments are not available.

### ACKNOWLEDGMENTS

The researchers are grateful to the authorities of the University of Mysore for providing the permission and facilities. Authors also thankful to Dr. Reddy's Laboratories limited, Hyderabad, India, for gifting pure fluconazole. Prof. K. Basavaiah wishes to express his gratitude to the UGC, New Delhi for award of UGC-BSR faculty fellowship.

### REFERENCES

1. O'Neil, 2006. The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals. 14th Edn., Wiley, New York, ISBN: 9780911910001, Pages: 2564.
2. Reynolds, J.E.F., 1996. Martindale: The Extra Pharmacopoeia. 31st Edn., The Pharmaceutical Press, London, UK, ISBN-13: 9780853693420, pp: 404-406.
3. Bennett, J.E., 2006. Antifungal Agents. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics, Brunton, L.L., J.S. Lazo and K.L. Parker (Eds.). 11th Edn., Chapter 48, McGraw-Hill, New York, USA, ISBN-13: 9780071608916, pp: 1225-1241.
4. Humphrey, M.J., S. Jevons and M.H. Tarbit, 1985. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother., 28: 648-653.

5. Correa, J.C.R. and H.R.N. Salgado, 2011. Review of fluconazole properties and analytical methods for its determination. Crit. Rev. Anal. Chem., 41: 270-279.
6. Decosterd, L.A., B. Rochat, B. Pesse, T. Mercier and F. Tissot *et al.*, 2010. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-*N*-oxide, anidulafungin and caspofungin. Antimicrob. Agents Chemother., 54: 5303-5315.
7. Wu, D., K.C. Wade, D.J. Paul and J.S. Barrett, 2009. A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with candida infections. Therapeut. Drug Monitor., 31: 703-709.
8. Sun, S., H. Lou, Y. Gao, P. Fan, B. Ma, W. Ge and X. Wang, 2004. Liquid chromatography-tandem mass spectrometric method for the analysis of fluconazole and evaluation of the impact of phenolic compounds on the concentration of fluconazole in *Candida albicans*. J. Pharmaceut. Biomed. Anal., 34: 1117-1124.
9. Eerkes, A., W.Z. Shou and W. Naidong, 2003. Liquid/liquid extraction using 96-well plate format in conjunction with hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the analysis of fluconazole in human plasma. J. Pharmaceut. Biomed. Anal., 31: 917-928.
10. Moraes, L.A., F.E. Lerner, M.E.A. Moraes, M.O. Moraes, G. Corso and G. de Nucci, 1999. Fluconazole bioequivalence study: Quantification by tandem mass spectrometry. Therapeut. Drug Monitor., 21: 200-207.
11. Beijnen, J.H., P.L. Meenhorst, R. van Gijn, W.A. Hazelager, C.H.W. Koks and W.J.M. Underberg, 1992. Erratum: J.H. Beijnen *et al.*, Gas chromatographic analysis, with electron capture detection, of the antifungal drug fluconazole in microvolumes of human plasma. J. Pharm. Biomed. Anal. 9, 1173-1175 (1991). J. Pharmaceut. Biomed. Anal., 10: 315-315.
12. Beijnen, J.H., P.L. Meenhorst, R. van Gijn, W.A. Hazelager, C.H.W. Koks and W.J.M. Underberg, 1991. Gas chromatographic analysis, with electron capture detection, of the antifungal drug fluconazole in microvolumes of human plasma. J. Pharmaceut. Biomed. Anal., 9: 1173-1175.
13. Rege, A.B., J.Y. Walker-Cador, R.A. Clark, J.J. Lertora, N.E. Hyslop Jr. and W.J. George, 1992. Rapid and sensitive assay for fluconazole which uses gas chromatography with electron capture detection. Antimicrob. Agents Chemother., 36: 647-650.
14. Macrae, P.V., 1990. Quantitative analysis of the antifungal agent, fluconazole, by capillary gas chromatography with ion-trap detection. Methodol. Surv. Biochem. Anal., 20: 145-152.
15. Harris, S.C., J.E. Wallace, G. Foulds and M.G. Rinaldi, 1989. Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob. Agents Chemother., 33: 714-716.

16. Debruyne, D., J.P. Ryckelynck, M.C. Bigot and M. Moulin, 1988. Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector. *J. Pharmaceut. Sci.*, 77: 534-535.
17. Wood, P.R. and M.H. Tarbit, 1986. Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine. *J. Chromatogr. B: Biomed. Sci. Applic.*, 383: 179-186.
18. Lima, D.M., G.P. Nunes Jr., P.H. Ferri and S.C. Santos, 2005. Determination of fluconazole in serum and amniotic fluid of rats by Gas-Chromatography/Mass Spectrometry (GC/MS). *Revista Brasileira Ciencias Farmaceuticas*, 41: 223-227.
19. Von Heeren, F., R. Tanner, R. Theurillat and W. Thormann, 1996. Determination of fluconazole in human plasma by micellar electrokinetic capillary chromatography with detection at 190 nm. *J. Chromatogr. A*, 745: 165-172.
20. Ershad, S. and S. Kangari, 2009. Preparation of a fluconazole potentiometric sensor and its application to pharmaceutical analysis and to drug recovery from biological fluids. *Int. J. Electrochem. Sci.*, 4: 1100-1108.
21. Hillis, J., I. Morelli, D. Neville, J. Fox and A.C. Leary, 2004. The validation of a bioanalytical method for the determination of fluconazole in human plasma. *Chromatographia*, 59: S203-S207.
22. Marchetti, O., P.A. Majcherczyk, M.P. Glauser, J. Bille, P. Moreillon and D. Sanglard, 2001. Sensitive bioassay for determination of fluconazole concentrations in plasma using a *Candida albicans* mutant hypersusceptible to azoles. *Antimicrob. Agents Chemother.*, 45: 696-700.
23. Hulsewede, J.W. and H. Dermoumi, 1996. Serum level determination of fluconazole by high-performance liquid chromatography and bioassay. *Zentralblatt Bakteriol.*, 283: 492-496.
24. Rex, J.H., L.H. Hanson, M.A. Amantea, D.A. Stevens and J.E. Bennett, 1991. Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. *Antimicrob. Agents Chemother.*, 35: 846-850.
25. Correa, J.C.R., C. Reichman, H.R.N. Salgado and C.D. Vianna-Soares, 2012. Performance characteristics of high performance liquid chromatography, first order derivative UV spectrophotometry and bioassay for fluconazole determination in capsules. *Quimica Nova*, 35: 530-534.
26. Elezovic, A., A. Elezovic and S. Hadzovic, 2011. Simple, inexpensive and ecologically friendly derivative spectrophotometric fluconazole assay from nail lacquer formulations. *Am. J. Anal. Chem.*, 2: 109-115.
27. Gondalia, R.P., D.P. Patel and P.J. Savaliya, 2010. Development and validation of UV spectrophotometric method for estimation of fluconazole in soft gelatin capsule. *Int. J. Pharm. Technol.*, 2: 938-944.
28. Sadasivudu, P., N. Shastri and M. Sadanandam, 2009. Development and validation of RP-HPLC and UV methods of analysis for fluconazole in pharmaceutical solid dosage forms. *Int. J. Chem. Tech. Res.*, 1: 1131-1136.
29. Aboul-Enein, H.Y., N.G. Goger and A. Turkalp, 2002. Quantitative determination of fluconazole in syrups by first order derivative spectrophotometry. *Anal. Lett.*, 35: 1193-1204.
30. Goger, N.G. and H.Y. Aboul-Enein, 2001. Quantitative determination of fluconazole in capsules and IV solutions by UV spectrophotometric methods. *Anal. Lett.*, 34: 2089-2098.
31. Lotfy, H., H.H. Monir and A.E.A.B. Abd El-Aleem, 2012. Novel Spectrophotometric methods for the determination of fluconazole in the presence of its oxidative degradation product. *J. Chilean Chem. Soc.*, 57: 1447-1455.
32. Rao, B.S.S., E.S. Kumar and G.K. Kumar, 2012. Methods development of fluconazole tablets (400 Mg). *Pharma Innov.*, 1: 113-115.
33. Pandey, S., P. Pandey, S. Dubey, U. Chaturvedi and A.K. Rai, 2012. Facile derivative UV spectroscopy method: Simultaneous estimation of tinidazole and fluconazole in combined tablet dosage form. *Thai J. Pharm. Sci.*, 36: 55-62.
34. Belal, F., M.K. Sharaf El-Din, M.I. Eid and R.M. El-Gamal, 2014. Micellar HPLC and derivative spectrophotometric methods for the simultaneous determination of fluconazole and tinidazole in pharmaceuticals and biological fluids. *J. Chromatogr. Sci.*, 52: 298-309.
35. Singh, A., P.K. Sharma and D.K. Majumdar, 2011. Development and validation of different UV-spectrophotometric methods for the estimation of fluconazole in bulk and in solid dosage form. *Indian J. Chem. Technol.*, 18: 357-362.
36. Alizadeh, N. and Z. Rezakhani, 2012. Extractive spectrophotometric determination of ketoconazole, clotrimazole and fluconazole by ion-pair complex formation with bromothymol blue and picric acid. *J. Chilean Chem. Soc.*, 57: 1104-1108.
37. Burlaka, Y.V., O.O. Tarkhanova, S.O. Vasyuk and I.M. Keitlin, 2010. Determination of fluconazole in pharmaceutical formulations by reaction with bromothymol blue. *Farmatsevtichnii Zhurnal*, 3: 69-75.
38. Jalali, F. and M.J. Rajabi, 2007. Extractive spectrophotometric determination of fluconazole by ion-pair complex formation with bromocresol green. *Chin. J. Chem.*, 25: 1300-1303.
39. Bai, J., Y. Jin, L. Bai and J. Wei, 2004. Determination of fluconazole eye drops by fluorospectrophotometry. *Disi Junyi Daxue Xuebao*, 25: 841-842.
40. Li, Y., 2001. Determination of fluconazole in capsules and injections by fluorimetry. *Guangdong Yaoxueyuan Xuebao*, 17: 49-50.
41. El-Bayoumi, A., A.A. El-Shanawany, M.E. El-Sadek and A.A. El-Sattar, 1997. Synchronous spectrofluorimetric determination of famotidine, fluconazole and ketoconazole in bulk powder and in pharmaceutical dosage forms. *Spectrosc. Lett.*, 30: 25-46.

42. Senyuva, H., T. Ozden and I. Aksahin, 2001. Quantitative determination of fluconazole in solid dosage forms by <sup>1</sup>H-NMR spectroscopy. *Gazi Universitesi Eczacilik Fakultesi Dergisi*, 18: 107-113.
43. Meshram, D., S. Bagade and M. Tajne, 2008. A simple TLC method for analysis of fluconazole in pharmaceutical dosage forms. *J. Planar Chromatogr. Modern TLC.*, 21: 191-195.
44. Shewiyo, D., E. Kaale, P. Risha, H. Sillo, B. Dejaegher, J. Smeyers-Verbeke and Y. Heyden, 2011. Development and validation of a normal-phase HPTLC-densitometric method for the quantitative analysis of fluconazole in tablets. *J. Planar Chromatogr.-Model TLC*, 24: 529-533.
45. Ramesh, B., P.S. Narayana, A.S. Reddy and P.S. Devi, 2011. Spectrodensitometric evaluation and determination of fluconazole and its impurities in pharmaceutical formulations by high performance thin layer chromatography. *J. Pharm. Res.*, 4: 1401-1404.
46. Yanamandra, R., A. Chaudhary, S.R. Bandaru, B. Patro, Y.L.N. Murthy, P.A. Ramaiah and C.S.P. Sastry, 2010. UPLC method for simultaneous separation and estimation of secnidazole, fluconazole and azithromycin in pharmaceutical dosage forms. *E-J. Chem.*, 7: S363-S371.
47. Jebaliya, H., M. Patel, Y. Jadeja, B. Dabhi and A. Shah, 2013. A comparative validation study of fluconazole by HPLC and UPLC with forced degradation study. *Chromatogr. Res. Int.* 10.1155/2013/673150
48. Correa, J.C.R., C. Reichman, C.D. Vianna-Soares and H.R.N. Salgado, 2011. Stability study of fluconazole applying validated bioassay and stability-indicating LC methods. *J. Anal. Bioanal. Tech.*, Vol. 2. 10.4172/2155-9872.1000126
49. Queiroz, K.M., M.L.M. Silva, N.D. Prado, P.M.A. Lima and R.D.L. Diniz *et al.*, 2009. Comparison of microbiological assay and HPLC-UV for determination of fluconazole in capsules. *Braz. J. Pharmaceut. Sci.*, 45: 693-700.
50. Hurtado, F.K., M.J. Souza, J. de Melo and C.M.B. Rolim, 2008. Microbiological assay and HPLC method for the determination of fluconazole in pharmaceutical injectable formulations. *Latin Am. J. Pharm.*, 27: 224-228.
51. Harod, S.S., N. Manocha, A. Hingole and P.K. Dubey, 2012. Development and validation of analytical method for Fluconazole and Ivermectin in tablet formulation by using RP-HPLC. *Int. Res. J. Pharm.*, 3: 257-261.
52. Bodepudi, C., S. Bantu, O.R.M. Kalyan, P. Shanmugasundaram and M.V. Aanandhi, 2011. Novel reverse phase HPLC method development and validation of fluconazole and tinidazole in a combined tablet dosage form. *Int. J. Chem. Tech. Res.*, 3: 1309-1317.
53. Meshram, D.B., S.B. Bagade and M.R. Tajne, 2009. Simple HPLC method for simultaneous estimation of fluconazole and tinidazole in combined dose tablet. *J. Chromatogr. Sci.*, 47: 885-888.
54. Yanamandra, R., A. Chaudhary, S.R. Bandaru, C.S.P. Sastry, B. Patro, Y.L.N. Murthy and P.A. Ramaiah, 2011. Development of a RP-UPLC method for the simultaneous analysis of secnidazole, fluconazole and azithromycin: Application in pharmaceuticals and human serum. *Int. J. Pharm. Tech. Res.*, 3: 1198-1207.
55. Abdel-Aleem, A.A., H.M. Lotfy and H.H. Monir, 2012. Stability-indicating high performance liquid chromatographic determination of fluconazole in the presence of its oxidative degradation-kinetic and stress study. *Int. Res. J. Pharm.*, 2: 6-12.
56. Lotfy, H.M., A.A.A.B. Abdel-Aleem and H.H. Monir, 2013. Stability-indicating high performance liquid chromatographic determination of fluconazole in the presence of its oxidative degradation product-kinetic and stress study. *J. Liquid Chromatogr. Relat. Technol.*, 36: 1013-1029.
57. Abdel-Moety, E.M., F.I. Khattab, K.M. Kelani and A.M. AbouAl-Alamein, 2003. Chromatographic determination of clotrimazole, ketoconazole and fluconazole in pharmaceutical formulations. *Il Farmaco*, 57: 931-938.
58. Hermawan, D., N.A.M. Ali, W.A. Wan Ibrahim and M.M. Sanagi, 2013. Analysis of fluconazole in human urine sample by high performance liquid chromatography method. *J. Phys. Conf. Ser.*, Vol. 423. 10.1088/1742-6596/423/1/012009
59. USP., 2012. United States pharmacopeia 35, National formulary-32. USP Convention, Fluconazole, Rockville, pp: 3204-3205.
60. Council of Europe, 2012. European pharmacopoeia. Edition 7.6, EDQM., Council of Europe, Strasbourg, France, pp: 4936-4937.
61. British Pharmacopoeia Commission, 2009. British pharmacopoeia. 1&2 Monograph No. 2287, Her Majesty's, Stationery Office, London.
62. Kucharsky, R.N.J. and L.A. Safarik, 1965. Titrations in Non-Aqueous Solvents. Elsevier Publishing Company, Amsterdam, Netherlands, pp: 94.
63. Kar, A., 2005. Pharmaceutical Drug Analysis: Methodology, Theory, Instrumentation, Pharmaceutical Assays, Cognate Assays. 2nd Edn., New Age International (P) Ltd., New Delhi, India, ISBN-13: 978-81-224-2718-9, Pages: 554.
64. Cairns, D., 2008. Essentials of Pharmaceutical Chemistry. 3rd Edn., Pharmaceutical Press, Cornwall, UK., ISBN-13: 978-0071417983, Pages: 304.